

**Supplemental Material**

**Table 1.** Scheduled visits for treatment, clinical and immunological assessment in the BVAC-C phase I trial.

Study timeline	Screening	Visit 1	Visit 2		Visit 3	Visit 4		Visit 5	Visit 6		Visit 7	Visit F
	-6 w ~-1 w	-2 w ~4 d	0 w ±2 d	0 w +1 d	2 w ±2 d	4 w ±2 d	4 w +1 d	6 w ±2 d	8 w ±2 d	8 w +1 d	10 w ±2 d	12 w ±2 d
Enrollment	•											
Lymphapheresis		•										
BVAC-C injection			•			•			•			
AE assessment	•	•	•	•	•	•	•	•	•	•	•	•
Serum cytokine assay			•	•			•	•		•	•	
CD4/CD8 T cell assay	•				•	•		•	•		•	•
Radiological assessment	•											•

Abbreviations: AE = Adverse Event; w = week; d = day; F = final

**Table 2.** Adverse events of any grade observed in the study ( $n = 11$ ).

Adverse events	$1 \times 10^7$ ( $n = 4$ )			$4 \times 10^7$ ( $n = 3$ )			$1 \times 10^8$ ( $n = 4$ )			Total ( $n = 11$ )		
	G1	G2	G3	G1	G2	G3	G1	G2	G3	G1 (%)	G2 (%)	G3 (%)
Respiratory, thoracic and mediastinal disorders												
Oropharyngeal pain	1	0	0	0	0	0	0	0	0	1 (9)	0	0
Cough	0	0	0	1	0	0	0	0	0	1 (9)	0	0
Productive cough	0	0	0	1	0	0	0	0	0	1 (9)	0	0
Dyspnea	0	0	0	1	0	0	0	0	0	1 (9)	0	0
Nervous system disorders												
Headache	1	0	0	1	0	0	1	0	0	3 (27)	0	0
Musculoskeletal and connective tissue disorders												
Myalgia	2	1	0	1	0	0	2	0	0	5 (45)	1 (9)	0
Pain in extremity	0	0	1	0	0	0	0	0	0	0	0	1 (9)
Bone pain	1	0	0	0	0	0	0	0	0	1 (9)	0	0
Back pain	0	0	0	0	0	0	0	1	0	0	1 (9)	0
Musculoskeletal pain	0	0	0	0	0	0	0	1	0	0	1 (9)	0
General disorders and administration site conditions												
Flank pain	1	0	0	0	0	0	0	0	0	1 (9)	0	0
Pyrexia	1	0	0	3	0	0	3	0	0	7 (63)	0	0
Asthenia	0	0	0	2	0	1	0	0	0	2 (18)	0	1 (9)
Edema peripheral	0	0	0	1	0	0	0	0	0	1 (9)	0	0
Chills	0	0	0	0	0	0	2	0	0	2 (18)	0	0
Fatigue	0	0	0	0	0	0	1	0	0	1 (9)	0	0

Gastrointestinal disorders												
Constipation	1	0	0	0	0	0	1	0	0	<b>2 (18)</b>	<b>0</b>	<b>0</b>
Dyspepsia	0	0	0	1	0	0	1	0	0	<b>2 (18)</b>	<b>0</b>	<b>0</b>
Abdominal distension	0	0	0	1	1	0	0	0	0	<b>1 (9)</b>	<b>1 (9)</b>	<b>0</b>
Ileus	0	0	0	1	0	1	0	0	0	<b>1 (9)</b>	<b>0</b>	<b>1 (9)</b>
Nausea	0	0	0	1	0	0	0	0	0	<b>1 (9)</b>	<b>0</b>	<b>0</b>
Stomatitis	0	0	0	1	1	0	0	0	0	<b>1 (9)</b>	<b>1 (9)</b>	<b>0</b>
Diarrhea	0	0	0	0	0	0	0	1	0	<b>0</b>	<b>1 (9)</b>	<b>0</b>
Vomiting	0	0	0	0	0	0	1	0	0	<b>1 (9)</b>	<b>0</b>	<b>0</b>
Metabolism and nutrition disorders												
Decreased appetite	0	1	0	0	0	0	0	0	0	<b>0</b>	<b>1 (9)</b>	<b>0</b>
Hyperkalemia	0	0	0	0	1	0	0	0	0	<b>0</b>	<b>1 (9)</b>	<b>0</b>
Hypoalbuminemia	0	0	0	0	2	1	0	0	0	<b>0</b>	<b>2 (18)</b>	<b>1 (9)</b>
Hypophagia	0	0	0	2	0	1	0	0	0	<b>2 (18)</b>	<b>0</b>	<b>1 (9)</b>
Neoplasms benign, malignant and unspecified												
Skin papilloma	0	1	0	0	0	0	0	0	0	<b>0</b>	<b>1 (9)</b>	<b>0</b>
Blood and lymphatic system disorders												
Anemia	0	0	0	1	1	1	1	2	1	<b>2 (18)</b>	<b>3 (27)</b>	<b>2 (18)</b>
Hepatobiliary disorders												
Ascites	0	0	0	0	0	1	0	0	0	<b>0</b>	<b>0</b>	<b>1 (9)</b>
Renal and urinary disorders												
Bladder infections and inflammation												
Nocturia	0	0	0	0	1	0	1	0	0	<b>1 (9)</b>	<b>1 (9)</b>	<b>0</b>
Ureteric stenosis	0	0	0	1	0	0	0	0	0	<b>1 (9)</b>	<b>0</b>	<b>0</b>
Incontinence	0	0	0	0	0	0	1	0	0	<b>1 (9)</b>	<b>0</b>	<b>0</b>

Investigations													
C-reactive protein increased	0	0	0	0	0	0	1	0	0	<b>1 (9)</b>	<b>0</b>	<b>0</b>	
Immune system disorders													
Cytokine release syndrome	0	0	0	0	0	0	0	1	0	<b>0</b>	<b>1 (9)</b>	<b>0</b>	
Injury, poisoning and procedural complications													
Ligament sprain	0	0	0	0	0	0	1	0	0	<b>1 (9)</b>	<b>0</b>	<b>0</b>	
Reproductive system and breast disorders													
Pelvic inflammatory disease	0	0	0	0	0	0	0	1	1	<b>0</b>	<b>1 (9)</b>	<b>1 (9)</b>	

---